TNF and myeloid sarcoma: Ultimately, while blocking all TNF signaling in MS and EAE can reduce its detrimental effects, it also reduces the beneficial aspects of TNFR2 signaling, leading to a net negative result for anti-TNF therapies in MS and EAE.